Aurobindo Pharma Ltd
NSE: AUROPHARMA BSE: 524804
₹1705
+10.50 (0.62%)
Fri, 06 Nov 2026, 10:02 pm
Market Cap (in Cr)97756.7
PE Ratio26.64
Dividend0.24
Health Technology
Pharmaceuticals: Other
24.5KAurobindo Pharma Income Statement
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 15.70B | 21.14B | 24.20B | 30.38B | 35.15B | 43.18B | 45.38B | 57.70B | 80.27B | 120.27B | 135.34B | 146.73B | 162.09B | 192.41B | 227.53B | 245.71B | 234.24B | 246.38B | 287.25B | 314.03B |
| Gross profit | 2.92B | 4.74B | 6.30B | 8.74B | 9.84B | 10.67B | 7.61B | 12.26B | 25.56B | 40.15B | 47.35B | 53.78B | 53.73B | 55.25B | 73.63B | 78.45B | 69.96B | 69.00B | 81.44B | 93.75B |
| Operating expenses (excl. COGS) | -2.07B | -2.90B | -4.13B | -4.58B | -3.64B | -3.12B | -4.24B | -6.39B | -7.93B | -18.37B | -21.52B | -25.74B | -23.50B | -24.97B | -34.62B | -34.77B | -36.66B | -43.25B | -39.24B | -45.18B |
| Selling/general/admin expenses, total | -1.95B | -2.75B | -4.01B | -4.50B | -3.55B | -2.82B | -4.13B | -5.92B | -7.24B | -16.71B | -20.83B | -24.91B | -22.74B | -24.09B | -33.63B | -33.80B | -35.98B | -42.22B | -38.28B | -43.83B |
| Research & development | -397.60M | -538.80M | -1.13B | -780.50M | -829.80M | -1.39B | -1.59B | -2.33B | -2.75B | -3.47B | -4.12B | -5.43B | -6.66B | -8.68B | -9.58B | -15.10B | -15.81B | -14.12B | -15.46B | -17.17B |
| Selling/general/admin expenses, other | -1.56B | -2.21B | -2.88B | -3.72B | -2.72B | -1.42B | -2.54B | -3.60B | -4.49B | -13.25B | -16.71B | -19.48B | -16.08B | -15.41B | -24.04B | -18.71B | -20.16B | -28.11B | -22.82B | -26.66B |
| Other operating expenses, total | -122.10M | -147.90M | -119.00M | -79.60M | -82.30M | -302.60M | -108.60M | -468.20M | -690.30M | -1.66B | -692.10M | -833.90M | -754.70M | -873.40M | -997.20M | -967.10M | -684.90M | -1.02B | -958.70M | -1.35B |
| Operating income | 841.80M | 1.84B | 2.17B | 4.15B | 6.21B | 7.55B | 3.37B | 5.86B | 17.63B | 21.78B | 25.82B | 28.04B | 30.23B | 30.28B | 39.01B | 43.69B | 33.30B | 25.75B | 42.20B | 48.58B |
| Non-operating income, total | 140.40M | 218.50M | 739.30M | -3.43B | 1.31B | 438.10M | -5.50B | -2.12B | -2.30B | -100.90M | 1.62B | 2.52B | 2.15B | 606.10M | -1.43B | 30.30B | 742.40M | 487.50M | 1.77B | 2.40B |
| Interest expense, net of interest capitalized | -691.00M | -864.50M | -621.10M | -825.70M | -624.90M | -443.70M | -2.56B | -2.49B | -3.10B | -1.60B | -2.57B | -667.20M | -775.70M | -1.63B | -1.60B | -744.90M | -486.40M | -1.40B | -2.90B | -4.57B |
| Interest capitalized | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-operating income, excl. interest expenses | 535.30M | 1.08B | 1.36B | -2.24B | 2.06B | 1.05B | 294.90M | 362.40M | 799.60M | 1.50B | 4.19B | 3.19B | 2.56B | 2.01B | 170.10M | 34.86B | 3.01B | 2.00B | 7.11B | 7.55B |
| Non-operating interest income | 86.90M | 410.90M | 261.80M | 93.60M | 52.90M | 21.70M | 56.60M | 29.20M | 37.80M | 155.60M | 103.70M | 161.50M | 120.20M | 137.80M | 209.10M | 223.70M | 316.00M | 1.46B | 2.86B | 3.53B |
| Miscellaneous non-operating expense | 448.40M | 673.10M | 1.10B | -2.33B | 2.01B | 1.03B | 238.30M | 333.20M | 761.80M | 1.34B | 4.07B | 3.02B | 2.44B | 1.87B | -39.00M | 34.64B | 2.70B | 542.90M | 4.25B | 4.02B |
| Unusual income/expense | 296.10M | -1.00M | -100.00K | -368.70M | -120.70M | -167.20M | -3.23B | — | — | — | — | — | 371.30M | 222.30M | 1.90M | -3.82B | -1.78B | -109.50M | -2.44B | -575.10M |
| Pretax income | 982.20M | 2.06B | 2.91B | 721.00M | 7.52B | 7.99B | -2.13B | 3.74B | 15.33B | 21.68B | 27.44B | 30.56B | 32.38B | 30.89B | 37.58B | 73.99B | 34.04B | 26.24B | 43.97B | 50.98B |
| Taxes | -271.10M | -39.60M | -531.30M | -208.40M | -1.91B | -2.25B | 888.10M | -827.10M | -3.63B | -5.97B | -7.21B | -7.60B | -8.18B | -7.27B | -8.99B | -20.10B | -7.26B | -6.85B | -12.11B | -15.83B |
| Non-controlling/minority interest | -14.10M | -11.00M | 3.40M | 500.00K | 3.20M | 3.90M | 6.40M | 24.60M | 37.80M | 45.10M | 15.00M | 4.70M | 2.60M | 2.30M | 14.50M | 10.20M | 10.40M | -1.50M | 40.00M | 23.10M |
| After tax other income/expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income before discontinued operations | 697.00M | 2.01B | 2.38B | 513.10M | 5.61B | 5.74B | -1.24B | 2.94B | 11.73B | 15.76B | 20.25B | 23.02B | 24.23B | 23.65B | 28.45B | 53.35B | 26.48B | 19.27B | 31.73B | 34.86B |
| Net income | 697.00M | 2.01B | 2.38B | 513.10M | 5.61B | 5.74B | -1.24B | 2.94B | 11.73B | 15.76B | 20.25B | 23.02B | 24.23B | 23.65B | 28.45B | 53.35B | 26.48B | 19.27B | 31.73B | 34.86B |
| Dilution adjustment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Preferred dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted net income available to common stockholders | 697.00M | 2.01B | 2.38B | 513.10M | 5.61B | 5.74B | -1.24B | 2.94B | 11.73B | 15.76B | 20.25B | 23.02B | 24.23B | 23.65B | 28.45B | 53.35B | 26.48B | 19.27B | 31.73B | 34.86B |
| Basic earnings per share (Basic EPS) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Diluted earnings per share (Diluted EPS) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | 1.56B | 2.84B | 3.18B | 5.43B | 7.70B | 9.26B | 5.37B | 8.35B | 20.75B | 25.11B | 29.75B | 32.32B | 35.81B | 36.96B | 48.67B | 54.24B | 44.56B | 38.20B | 57.12B | 64.49B |
| EBIT | 841.80M | 1.84B | 2.17B | 4.15B | 6.21B | 7.55B | 3.37B | 5.86B | 17.63B | 21.78B | 25.82B | 28.04B | 30.23B | 30.28B | 39.01B | 43.69B | 33.30B | 25.75B | 42.20B | 48.58B |
| Total operating expenses | -14.86B | -19.30B | -22.02B | -26.23B | -28.94B | -35.63B | -42.01B | -51.84B | -62.65B | -98.49B | -109.52B | -118.69B | -131.87B | -162.13B | -188.52B | -202.03B | -200.94B | -220.62B | -245.05B | -265.45B |
| Prepaid expenses | 176.80M | 192.00M | 137.00M | 621.10M | 384.90M | 301.90M | 93.10M | 79.90M | — | — | — | — | — | — | — | — | — | — | — | — |
| Deferred income, current | — | — | — | — | — | — | — | — | 134.60M | 44.60M | 57.30M | 390.00M | 671.70M | 1.67B | 222.20M | 110.30M | 5.68B | 3.89B | 2.70B | 1.04B |
| Capital and operating lease obligations | 1.90M | 1.90M | 1.20M | 400.00K | — | 0 | 0 | 0 | 0 | 0 | 0 | 269.60M | 488.80M | 488.80M | 2.66B | 2.66B | 2.49B | 3.22B | 2.53B | 2.39B |
| Operating lease liabilities | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Deferred tax liabilities | 725.60M | 681.90M | 733.40M | 790.40M | 953.50M | 1.40B | 1.71B | 2.11B | 2.05B | 2.11B | 239.60M | 493.00M | 2.35B | 2.81B | 2.92B | 5.75B | 4.11B | 3.90B | 3.57B | 3.03B |
| Deferred income, non-current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | 363.50M | 475.70M |
| Minority interest | 24.30M | 35.40M | 32.00M | 31.50M | 43.30M | 91.20M | 102.10M | 110.00M | 256.70M | 258.20M | 25.50M | 20.80M | 18.20M | 15.90M | 1.40M | -8.80M | -19.30M | 120.00M | 80.00M | -63.90M |
| Change in accrued expenses | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Common dividends paid | -30.30M | -92.30M | -157.10M | -393.20M | -288.50M | -474.70M | -338.20M | -674.30M | -595.50M | -1.80B | -1.62B | -1.37B | -2.64B | -1.60B | -1.88B | -2.34B | -2.64B | -4.40B | -2.64B | -10.40M |
| Preferred dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
